促性腺激素释放激素类似物对不同血清中网膜素-1水平的特发性矮小症患儿的治疗效果OACSTPCD

Objective To analyze the therapeutic effects of gonadotropin-releasing hormone analogues on idio-pathic short stature(ISS)children with different serum omentin-1 levels.Methods The study selected 95 ISS children treated at our hospital from August 2022 to March 2023.Based on an omentin-1 threshold of 58.91 ng/mL,47 children with omentin-1 levels＜58.91 ng/mL were categorized as the low-expression group,while 48 children with omentin-1 levels ≥58.91 ng/mL were categorized as the high-expression group.Both groups were treated with gonadotropin-re-leasing hormone analogues.The study compared physical development indicators,related growth factors,bone metabolism markers,vitamin D,trace elements,and thyroid function indicators between the two groups.Results Post-treatment,both groups exhibited increased growth velocity,height,bone age,predicted adult height,insulin-like growth factor 1(IGF-1),bone density,bone alkaline phosphatase(BALP),type Ⅰ procollagen N-terminal propeptide(PINP),vi-tamin D,zinc,magnesium,and calcium levels,with the high-expression group showing more significant improvements.The levels of growth hormone-releasing peptide(Ghrelin),appetite suppressor 1(nesfatin-1),and β-C-terminal telopeptide of type Ⅰ collagen(β-CTX)decreased,with a more pronounced reduction in the high-expression group(P＜0.05).There were no statistically significant differences in thyroid-stimulating hormone(TSH),free triiodothyronine(FT3),and free thyroxine(FT4)levels before and after treatment,nor between the two groups(P＞0.05).Conclusion Treatment with gonadotropin-releasing hormone analogues is effective in ISS children,with more significant improvements in physical development,related growth factors,and bone metabolism in children with high omentin-1 expression.Vita-min D and trace element levels also improved significantly,while thyroid function remained stable.